Track market-moving stories before they get noisy

AWM Investment Company Inc. bought a new position in shares of Progyny, Inc. (NASDAQ:PGNY – Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 220,000 shares of the company’s stock, valued at approximately $6,343,000. AWM Investment Company Inc. owned about 0.29% of Progyny at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Progyny in the second quarter worth approximately $334,426,000. Wellington Management Group LLP raised its holdings in Progyny by 260.9% during the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after buying an additional 1,621,688 shares during the last quarter. Fort Washington Investment Advisors Inc. OH raised its holdings in Progyny by 46.9% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock valued at $45,734,000 after buying an additional 859,289 shares during the last quarter. Loomis Sayles & Co. L P purchased a new stake in Progyny during the 4th quarter valued at $19,917,000. Finally, William Blair Investment Management LLC purchased a new stake in Progyny during the 2nd quarter valued at $16,807,000. 94.93% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades Several equities analysts have recently commented on the stock. Citigroup reaffirmed an “outperform” rating on shares of Progyny in a research note on Monday, May 11th. Canaccord Genuity Group set a $35.00 price target on Progyny in a report on Friday, August 7th. Leerink Partners set a $38.00 price target on Progyny in a report on Wednesday, July 22nd. Zacks Research upgraded Progyny from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 8th. Finally, Wells Fargo & Company assumed coverage on Progyny in a report on Thursday, August 20th. They issued an “overweight” rating and a $37.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.91.

Read Our Latest Research Report on PGNY Progyny Stock Up 1.5% Progyny stock opened at $25.82 on Wednesday. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $33.06. The company has a market capitalization of $1.98 billion, a P/E ratio of 28.07, a PEG ratio of 1.85 and a beta of 1.01. The stock’s 50 day moving average is $29.08 and its 200 day moving average is $23.55.

Progyny (NASDAQ:PGNY – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. The business had revenue of $350.51 million during the quarter, compared to analysts’ expectations of $349.05 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.19 earnings per share. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, equities analysts expect that Progyny, Inc. will post 1.19 EPS for the current year.

Progyny declared that its board has approved a stock repurchase plan on Tuesday, May 26th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to reacquire up to 10.3% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its shares are undervalued.

Insider Transactions at Progyny In other news, insider Geoffrey Clapp sold 1,530 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a total transaction of $39,137.40. Following the completion of the sale, the insider owned 59,117 shares of the company’s stock, valued at $1,512,212.86. The trade was a 2.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Mark S. Livingston sold 2,517 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $25.50, for a total value of $64,183.50. Following the completion of the sale, the chief financial officer owned 74,688 shares of the company’s stock, valued at approximately $1,904,544. The trade was a 3.26% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 13,563 shares of company stock valued at $351,968. 9.90% of the stock is owned by company insiders.

Progyny Profile (Free Report)

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.

Further Reading Five stocks we like better than Progyny Pathward’s Credit Scare Tests Its Comeback Story Wiring the AI Boom: Rumble’s $13.7B Pivot StoneX: Too Far Too Fast? DICK’s Sporting Goods Faces Pain Now for a Bigger Prize Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY – Free Report).

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.

3 Best Stocks to Buy That You’ve Probably Never Heard OfProgyny NASDAQ: PGNY CEO Pete Anevski said the company expects member engagement and utilization to rebound following a more pronounced summer seasonal slowdown, while early renewal and new-client commitments have increased management’s confidence in its outlook for the remainder of the year.

Speaking at the 46th Annual Canaccord Genuity Growth Conference, Anevski said Progyny has visibility into scheduled appointments for approximately the next six weeks and uses models to forecast utilization beyond that period. He said the company typically experiences seasonality in the second half of July and August, as some members delay fertility treatment because of summer travel, weddings and other personal plans.

Get Progyny alerts:

This year’s slowdown has been sharper than in recent years and more comparable to 2022, he said. However, Anevski said September appointment visibility indicates engagement and utilization returning to levels seen during the first half of the year.

“We wouldn’t put out guidance and expectations if we weren’t” comfortable with the outlook, Anevski said, adding that the early September activity is consistent with first-half trends.

Renewal commitments arrive earlier
Anevski said Progyny has received enough renewal commitments to “essentially de-risk” its renewal rates for next year earlier than it normally would in a sales cycle. About one-third of the company’s clients come up for renewal annually, generally under three-year contracts, he said.

Some employer clients renew directly, while others conduct requests for proposals or market checks. Anevski attributed the earlier decisions in part to broader medical-cost pressures facing employers. He said clients have not identified issues with Progyny’s reporting, member experience or performance.

Progyny also is seeing stronger early new-business commitments than it did at the same point last year, both in covered lives and expected contribution from those lives, according to Anevski. The company’s annual sales target is generally at least 1 million lives, and he said management expects to reach that goal based on current activity and the remaining pipeline.

While it is too early to quantify expansion activity at renewing clients, Anevski said Progyny historically sees roughly 20% to 30% of clients add something to their benefits. Potential additions include egg freezing, additional fertility treatment cycles, adoption and surrogacy coverage, global coverage, and ancillary postpartum maternity and menopause offerings.

He added that the company has received no indications that clients plan to reduce benefits.

More competitive replacement opportunities
The mix of early new-business commitments has included a higher proportion of “brownfield” opportunities than greenfield opportunities, Anevski said. He defined brownfield opportunities as employers that already offer fertility coverage through a health plan or another specialized provider.

According to Anevski, employers facing elevated medical-cost inflation are examining programs where they already spend money and seeking ways to improve efficiency. He said Progyny’s average cost per utilizer has risen relatively modestly over time compared with broader medical-cost inflation, which he characterized as running in the high-single-digit to low-double-digit range and expected to remain elevated next year.

Anevski also said the company’s client base has broadened substantially since its early years. Progyny began with five clients across two industries, including four technology clients, and has expanded into more than 45 industries, he said. The company generally sells into at least two-thirds of the industries it serves in a given year, although the specific industries vary.

He said adoption by major employers can encourage other companies within an industry to add the benefit as they compete for talent. Anevski cited the average age of women undergoing in vitro fertilization as 36, with much of Progyny’s utilization occurring among people ages 32 to 40. He said infertility affects one in five people in the U.S.

ROI, health-plan partnerships and cost management
Anevski distinguished Progyny’s offerings from traditional wellness programs, arguing that the company provides employers with hard-dollar savings calculations and detailed quarterly reporting. He said transparency around program costs, member outcomes and savings has supported Progyny’s 99% retention rate for 10 consecutive years.

He said health plans historically have not focused heavily on fertility-benefit management because their administrative-services business model does not necessarily produce more revenue from offering the coverage. In contrast, Progyny operates a proprietary provider network, offers care advocates and tracks outcomes, Anevski said.

The company has partnered with health plans, including Cigna, which began an expanded partnership effective in September of the prior year. Anevski said the current cycle is the first full sales season for that relationship and that Progyny is holding discussions with additional health plans regarding similar partnerships.

On medical-cost trends, Anevski said Progyny’s scale and network relationships have helped it contain provider rates, which he described as flat to down over time depending on the clinic. He also said the company’s improving outcomes contribute to savings for clients.

Expanded products and small-employer market
Progyny has approximately 7 million covered lives, with roughly 2.7 million having access to one or more expanded products, Anevski said. Those offerings include postpartum maternity and menopause programs, as well as Progyny Select.

Progyny Select is designed for employers with as few as 100 employees that typically purchase benefits on a fully insured, premium-based model. The product provides more predictable costs for smaller employers while placing them in a broader risk pool, Anevski said.

He said the company is working with channel partners, general agents and professional employer organizations to expand distribution of Progyny Select through broker networks. The offering increased Progyny’s estimated total addressable market by 50 million lives, to 155 million lives from 105 million previously, according to Anevski.

About Progyny (NASDAQ:PGNY)Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Progyny Right Now?Before you consider Progyny, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.

While Progyny currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Wall Street expects a year-over-year increase in earnings on higher revenues when Progyny (PGNY - Free Report) reports results for the quarter ended June 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 6. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis provider of fertility and family building benefits is expected to post quarterly earnings of $0.51 per share in its upcoming report, which represents a year-over-year change of +6.3%.

Revenues are expected to be $349.19 million, up 4.9% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 7.14% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Progyny?For Progyny, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -1.96%.

On the other hand, the stock currently carries a Zacks Rank of #1.

So, this combination makes it difficult to conclusively predict that Progyny will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Progyny would post earnings of $0.44 per share when it actually produced earnings of $0.50, delivering a surprise of +13.64%.

Over the last four quarters, the company has beaten consensus EPS estimates four times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Progyny doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

An Industry Player's Expected ResultsCharles River Laboratories (CRL - Free Report) , another stock in the Zacks Medical Services industry, is expected to report earnings per share of $2.72 for the quarter ended June 2026. This estimate points to a year-over-year change of -12.8%. Revenues for the quarter are expected to be $970.77 million, down 6% from the year-ago quarter.

Over the last 30 days, the consensus EPS estimate for Charles River has been revised 0.7% up to the current level. Nevertheless, the company now has an Earnings ESP of +1.43%, reflecting a higher Most Accurate Estimate.

This Earnings ESP, combined with its Zacks Rank #2 (Buy), suggests that Charles River will most likely beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.